spacer
home > ebr > spring 2002 > letter from ontario
PUBLICATIONS
European Biopharmaceutical Review

Letter from Ontario

BIO 2002 - the largest annual international meeting of the life science sector - is fast approaching, and is hosted this year, and for the third time in its history, by the city of Toronto in Ontario, Canada. Many in the life sciences in Europe and elsewhere in North America are aware of Canada's strengths in terms of its life science research base, pharmaceutical development expertise (within large pharma and contract development organisations), and some of the more interesting aspects of its intellectual property laws. However, perhaps less widely known is the extent to which federal and regional government support (structurally as well as financially), coupled with sharpening local and international investor interest have been shaping the development of several thriving biotechnology clusters.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Helen Abbott, Editor of EBR
spacer
Dr Helen Abbott
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

The key to tackling drug development complexity: Collaboration.

Laupheim and Ravensburg, Germany, Milford, MA, and Skokie, IL, USA, July 6, 2020 – Vetter and Rentschler Biopharma, two globally operating Contract Development and Manufacturing Organizations (CDMOs), today announced their strategic collaboration, to enhance their services and offer complementary skills and experience along the biopharmaceutical value chain. With drug development growing increasingly complex and cost-intensive, biopharmaceutical companies are under significant pressure to streamline their products’ path to market. The desired goal of the collaboration is to create long-term value through the alignment of manufacturing approaches that enable clients to bring their products to patients more easily and faster.
More info >>

White Papers

Characterisation of Biopharmaceutical Proteins

Reading Scientific Services Ltd (RSSL)

Over the next five years it is anticipated that there is going to be an explosion in the numbers of biosimilar products coming to market as patents expire. Consequently, in line with regulatory guidance, there will be a commensurate need to provide full characterisation of such biopharmaceuticals. The purpose of this article is to describe the array of the more common techniques used in biopharmaceutical characterisation (typically of protein or polypeptide). For full characterisation of a protein, the protein�s primary, secondary and tertiary structure as well as its physiochemical properties should be assessed.
More info >>

 
Industry Events

World Vaccine Congress Washington

27-29 September 2020, Walter E Washington Convention Center, Washington, US

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement